We confirmed that IMC-F106C recognized PRAME-pHLA on the cancer cell surface, redirected donor T cells, and efficiently mounted an anti-PRAME-specific antitumor response (i.e. CD8+ IFNγ release and cytolysis). The gene discussed is CD8A; the disease is cancer.